Literature DB >> 18081831

Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls.

A Pavlova1, A Diaz-Lacava, H Zeitler, J Satoguina, B Niemann, M Krause, I Scharrer, A Hoerauf, T Wienker, J Oldenburg.   

Abstract

Acquired haemophilia (AH) is an autoimmune disorder characterized by autoantibodies against endogenous factor VIII (FVIII). Half of the patients present with an underlying disease known to cause the FVIII autoantibodies whereas in the other half the disease is of idiopathic nature. Recently, it has been shown that variants of the polymorphic cytotoxic T lymphocyte antigen-4 (CTLA-4) gene are associated with autoimmune diseases and also represent a risk factor for inhibitor formation in inherited haemophilia A. In the present study, we investigated whether CTLA-4 variants also play a role in the pathogenesis of AH. Therefore, we analyzed three single nucleotide polymorphisms (SNPs) of the CTLA-4 gene (-318 C/T, +49 A/G and CT60 A/G) in 57 AH patients and 98 controls. The CTLA-4 + 49 G allele occurred with a significantly higher frequency in patients with AH compared with controls [odds ratio (OR) = 2.17, 95% confidence interval (CI): 1.36-3.48, P = 0.001]. This effect was mainly caused by a higher frequency of the 49 G allele in female patients (OR = 5.1, 95% CI: 1.76-15.02, P = 0.002), whereas in males the frequencies were not significantly different (OR = 1.4, P = 0.5). A higher frequency of the G allele was also observed in the subcohort with AH and underlying autoimmune disease (OR = 3.1, P = 0.04). Our observations of a higher frequency of the CTLA-4 + 49 A/G SNP in AH patients are in concordance with findings in other autoimmune disorders. In conclusion, on the background of the CTLA-4 gene polymorphism, further genetic and/or environmental factors might contribute to and finally trigger the clinical manifestation of AH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18081831     DOI: 10.1111/j.1365-2516.2007.01618.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  9 in total

Review 1.  FVIII inhibitors: pathogenesis and avoidance.

Authors:  Jan Astermark
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

Review 2.  Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice.

Authors:  Allyson M Pishko; Bhavya S Doshi
Journal:  J Blood Med       Date:  2022-05-11

Review 3.  Immune response to FVIII in hemophilia A: an overview of risk factors.

Authors:  Kanjaksha Ghosh; Shrimati Shetty
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

4.  A 75-year-old woman with acquired haemophilia disguised by warfarin treatment.

Authors:  Sarah Lawless; Gary Benson
Journal:  BMJ Case Rep       Date:  2015-10-06

5.  Successful Long Term Eradication of Factor VIII Inhibitor in Patients with Acquired Haemophilia A in Saudi Arabia.

Authors:  Galila Zaher; Soheir Adam
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-04-02       Impact factor: 2.576

6.  Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A.

Authors:  Silvia Spena; Andrea Cairo; Emanuela Pappalardo; Marcin M Gorski; Isabella Garagiola; Shermarke Hassan; Roberta Gualtierotti; Flora Peyvandi
Journal:  Haemophilia       Date:  2022-02-19       Impact factor: 4.263

7.  Acquired hemophilia A: a frequently overlooked autoimmune hemorrhagic disorder.

Authors:  Yoshihiko Sakurai; Tomohiro Takeda
Journal:  J Immunol Res       Date:  2014-03-24       Impact factor: 4.818

8.  Polymorphisms in the cytotoxic T lymphocyte-associated protein-4 immune regulatory gene and their impact on inhibitor development in patients with hemophilia A.

Authors:  Aveen M Raouf Abdulqader; Ali Ibrahim Mohammed; Shwan Rachid
Journal:  J Int Med Res       Date:  2019-09-15       Impact factor: 1.671

9.  Important roles of the human leukocyte antigen class I and II molecules and their associated genes in the autoimmune coagulation factor XIII deficiency via whole-exome sequencing analysis.

Authors:  Tsukasa Osaki; Masayoshi Souri; Akitada Ichinose
Journal:  PLoS One       Date:  2021-09-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.